Inovio rises, Macau casino operators dip again as quarantine in China expands » 10:5201/2301/23/20
INO, LVS, WYNN, MLCO, TWST, CODX, CERS
Shares of Inovio (INO)…
Piper says Inovio grant builds on significant work on coronavirus vaccines » 10:4501/2301/23/20
Piper Sandler analyst…
Piper Sandler analyst Christopher Raymond noted that the Coalition for Epidemic Preparedness Innovations is providing a $9M grant to Inovio for the development of a vaccine against coronavirus 2019-nCoV, which he said builds on the company's significant work on coronavirus vaccines given that CEPI is currently funding Inovio's work on MERS, which is another coronavirus. However, while today's news "underscores the importance of Inovio's science in the global effort to counter pandemics," Raymond noted that any approval and stockpile order is "likely years out" and he doesn't see a meaningful P&L impact in the near-term. He keeps an Overweight rating and $8 price target on Inovio shares, which are up 21c, or 6%, to $3.65 in morning trading.
Inovio selected by CEPI todevelop vaccine against new coronavirus » 09:1801/2301/23/20
Inovio (INO) has been…
Inovio (INO) has been awarded a grant of up to $9M by the Coalition for Epidemic Preparedness Innovations, or CEPI, to develop a vaccine against the recently emerged strain of coronavirus that has killed numerous people and infected hundreds more in China to date. This initial CEPI funding will support Inovio's preclinical and clinical development through Phase 1 human testing of INO-4800, its new coronavirus vaccine matched to the outbreak strain. CEPI previously awarded Inovio a grant of up to $56M for the development of vaccines against Lassa fever and Middle East Respiratory Syndrome, also caused by a coronavirus. In a recently published paper in Lancet Infectious Diseases, Inovio's Phase 1 study of its MERS-CoV vaccine demonstrated it was well tolerated and furthermore induced high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Inovio's collaborators in this coronavirus vaccine development include the Wistar Institute, VGXI, a fully owned subsidiary of GeneOne Life Science, and Twist Bioscience (TWST).
Antibiotics stocks rise, travel names slide as new virus spreads through China » 10:2401/2101/21/20
RCL, NVAX, INO, BCRX, LVS, WYNN, MLCO, LVMUY, DAL, AAL, ZNH, CCL
Shares of antibiotics…
Novavax soars 64% as unknown virus spreads through China » 09:2901/2101/21/20
NVAX, INO, BCRX
Shares of antibiotics…
Shares of antibiotics developer Novavax (NVAX) are soaring amid reports that a new respiratory virus has infected more than 200 people in China. Zhong Nanshan, who leads China's National Health Commission, told China's official state-run news organization Xinhua that two cases of human-to-human transmission had been confirmed in China, one in Wuhan and one in Guangdong. Shares of Novavax are up 64%, or $3.65, to $9.39 in premarket trading. Meanwhile, Inovio Pharmaceuticals (INO) is up 14% to $3.75 and BioCryst Pharmaceuticals (BCRX) is up 11% to $3.09.
|Over a week ago|
Piper 'incrementally positive' on Inovio after management meetings » 05:1701/1001/10/20
Piper Sandler analyst…
Piper Sandler analyst Christopher Raymond is "incrementally positive" on Inovio Pharmaceuticals shares after hosting management meetings. While recent execution and timeline adherence "has been a work in progress," the stock reflects very little value attribution from the company's broad developmental effort, Raymond tells investors in a research note. The analyst expects at least four data events/catalysts this year and thinks the Street is either not aware of or not anticipating these to be positive events. "Any inkling" of proof of concept this year from any program could result in significant upside to the stock, says Raymond, who notes his $8 price target assumes success from just one program, Inovio's VGX-3100 for cervical dysplasia. The analyst keeps an Overweight rating on Inovio.
Inovio management to meet with Piper Jaffray » 04:5501/0801/08/20
Meeting to be held in New…
Meeting to be held in New York on January 8 hosted by Piper Jaffray.
BLS Pharma alleges Inovio breached contract for injection system » 12:3501/0701/07/20
BLS Pharma filed a…
BLS Pharma filed a complaint late last month against Genetronics and Inovio Pharmaceuticals (INO) for breaching a contract to supply a needle-free injection system that BLS Pharma was using to develop a drug-device combination, or DDC, for testosterone replacement therapy. The shareholders of BLS Pharma previously developed the needleless injector technology, called "Zetajet," and sold the intellectual property rights for it to Inovio and Genetronics, with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request. Under the agreement, BLS Pharma ordered 25,000 Zetajet units to prepare for its clinical trials on the DDC and was assured that the order was "in process." In September, BLS Pharma and Genetronics discussed the logistics of the syringe supply, and BLS Pharma's plan to offer the product for patients with hypogonadism and as a treatment for transgender males. The next business day, Inovio and Genetronics informed BLS Pharma they would not be supplying the syringes. This breach of contract eliminated BLS Pharma's ability to bring the DDC to market. "We are disappointed that we cannot offer this solution for male hypogonadism and to the transgender community, who have historically been marginalized by the medical and pharmaceutical community," stated Mark Logomasini, CEO of BLS Pharma. The testosterone treatment market is valued at $1.3B-$1.8B dollars annually. BLS Pharma estimated its lost profits due to the breach of contract to be at least $72.9M.
Cantor reiterates Overweight rating, $12 price target on Inovio » 06:5401/0601/06/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Charles Duncan attributes the "modestly disappointing" delayed BLA filling for VGX-3100 in cervical dysplasia to slower than expected enrollment in the second Phase 3 study. The analyst, however, prefers "modulated" enrollment while maintaining stringent inclusion and exclusion criteria. In addition, he believes the first key de-risking event for the cervical dysplasia program is the Phase 3 REVEAL-1 efficacy data. The analyst anticipates top-line results for REVEAL-1 in Q4 of 2020 and believes Inovio can deliver on this timeline as enrollment completion occurred in late June 2019. Duncan reiterates an Overweight rating on Inovio Pharmaceuticals with a $12 price target.
Inovio submission guidance delay leaves Stifel 'incrementally negative' » 12:5501/0301/03/20
Stifel analyst Stephen…
Stifel analyst Stephen Willey maintained a Buy rating and $7 price target Inovio, but noted that the company's updated BLA submission guidance for VGX-3100, which is now 12-18 months beyond the previously issued guidance, "represents an incrementally negative data point which further stretches [the analyst's] confidence in management's ability to efficiently execute on a P3 development program," and added that the asset in question represents "the primary driver of valuation" in the firm's model. Willey said this update will require changing his model to "provide a bridge to longer-term profitability."